DB:PCBK

Stock Analysis Report

Executive Summary

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer.


Snowflake Analysis

Excellent balance sheet and slightly overvalued.

Share Price & News

How has Sesen Bio's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PCBK's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-5.7%

PCBK

-4.3%

DE Biotechs

-4.7%

DE Market


1 Year Return

6.1%

PCBK

5.5%

DE Biotechs

8.3%

DE Market

Return vs Industry: PCBK matched the German Biotechs industry which returned 5.5% over the past year.

Return vs Market: PCBK underperformed the German Market which returned 8.3% over the past year.


Shareholder returns

PCBKIndustryMarket
7 Day-5.7%-4.3%-4.7%
30 Day-9.7%-6.7%-4.0%
90 Day-26.2%0.4%-1.4%
1 Year6.1%6.1%5.8%5.5%11.7%8.3%
3 Year-60.2%-60.2%40.9%39.4%11.4%1.6%
5 Yearn/a10.9%8.6%15.1%-0.7%

Price Volatility Vs. Market

How volatile is Sesen Bio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Sesen Bio undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PCBK (€0.75) is trading below our estimate of fair value (€22.58)

Significantly Below Fair Value: PCBK is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PCBK is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: PCBK is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PCBK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PCBK is overvalued based on its PB Ratio (33.8x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Sesen Bio forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

47.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PCBK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PCBK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PCBK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PCBK is forecast to have no revenue next year.

High Growth Revenue: PCBK is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PCBK's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Sesen Bio performed over the past 5 years?

-15.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PCBK is currently unprofitable.

Growing Profit Margin: PCBK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PCBK is unprofitable, and losses have increased over the past 5 years at a rate of -15.3% per year.

Accelerating Growth: Unable to compare PCBK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PCBK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: PCBK has a negative Return on Equity (-3271.34%), as it is currently unprofitable.


Next Steps

Financial Health

How is Sesen Bio's financial position?


Financial Position Analysis

Short Term Liabilities: PCBK's short term assets ($59.4M) exceed its short term liabilities ($9.1M).

Long Term Liabilities: PCBK's short term assets ($59.4M) do not cover its long term liabilities ($107.8M).


Debt to Equity History and Analysis

Debt Level: PCBK is debt free.

Reducing Debt: PCBK has no debt compared to 5 years ago when its debt to equity ratio was 11.6%.


Balance Sheet

Inventory Level: PCBK has a low level of unsold assets or inventory.

Debt Coverage by Assets: PCBK's debt is not covered by short term assets (assets are -1563.5x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PCBK has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: PCBK has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 1% each year.


Next Steps

Dividend

What is Sesen Bio's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PCBK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate PCBK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PCBK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PCBK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PCBK's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.5yrs

Average management tenure


CEO

Thomas Cannell (57yo)

1.5yrs

Tenure

US$2,009,874

Compensation

Dr. Thomas R. Cannell, DVM, is President, Chief Executive Officer and Director at Sesen Bio, Inc. since August 7, 2018. He served as Chief Operating Officer of Orexigen Therapeutics, Inc. since June 8, 201 ...


CEO Compensation Analysis

Compensation vs Market: Thomas's total compensation ($USD2.01M) is above average for companies of similar size in the German market ($USD414.81K).

Compensation vs Earnings: Insufficient data to compare Thomas's compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Thomas Cannell
President1.5yrsUS$2.01mno data
Dennis Kim
Chief Medical Officer1.2yrsUS$709.28k0.019% $15.7k
K. Garcia
Co-Founder & Member of Scientific Advisory Board0yrsno datano data
Gregory Verdine
Co-Founder0yrsno datano data
Casey Weaver
Co-Founder & Member of Scientific Advisory Board0yrsno datano data
Monica Forbes
Chief Financial Officer0.5yrsno datano data
Kirstin Anderson
Corporate Controller & Principal Accounting Officer0.5yrsno data0.031% $25.3k
Glen MacDonald
Chief Technology Officer0yrsno datano data
Erin Clark
Vice President of Corporate Strategy & Investor Relations0yrsno datano data
Mark Sullivan
General Counsel & Corporate Secretary0.5yrsno datano data

0.5yrs

Average Tenure

50yo

Average Age

Experienced Management: PCBK's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Thomas Cannell
President1.5yrsUS$2.01mno data
K. Garcia
Co-Founder & Member of Scientific Advisory Board0yrsno datano data
Casey Weaver
Co-Founder & Member of Scientific Advisory Board0yrsno datano data
Daniel Lynch
Independent Director6yrsUS$130.30k0.068% $55.6k
Wendy Dixon
Chairman3.2yrsUS$257.57kno data
Patricia D'Amore
Member of Scientific Advisory Board0yrsno datano data
Jane Pritchett Henderson
Independent Director6yrsUS$133.43kno data
Peter Campochiaro
Member of Scientific Advisory Board0yrsno datano data
Jay Duker
Independent Director5.1yrsUS$113.78kno data
Reza Dana
Member of Scientific Advisory Board0yrsno datano data

5.1yrs

Average Tenure

60.5yo

Average Age

Experienced Board: PCBK's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 68.6%.


Top Shareholders

Company Information

Sesen Bio, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sesen Bio, Inc.
  • Ticker: PCBK
  • Exchange: DB
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$89.103m
  • Listing Market Cap: US$82.091m
  • Shares outstanding: 104.68m
  • Website: https://www.sesenbio.com

Number of Employees


Location

  • Sesen Bio, Inc.
  • 245 First Street
  • Suite 1800
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SESNNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDFeb 2014
PCBKDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2014
0IFZLSE (London Stock Exchange)YesCommon StockGBUSDFeb 2014

Biography

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer. The company’s lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate, which is in Phase I/II clinical trials for use in the treatment of various types of EpCAM-positive solid tumors. It is also developing Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of high-risk NMIBC; and Vicinium in combination with AstraZeneca’s checkpoint inhibitor that is in Phase I/IIa clinical trials for the treatment of squamous cell carcinoma of the head and neck. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 22:56
End of Day Share Price2020/02/24 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.